Fiona Stanley Hospital

SOUTH SAN FRANCISCO, Calif., Sept. 2, 2024 /PRNewswire/ -- IgGenix, Inc., a preclinical antibody discovery and development company taking a revolutionary approach to address IgE-mediated diseases, presented exciting data on the company's lead candidate, IGNX001, an IgG4 monoclonal antibody-based therapeutic for peanut allergy. These data were presented during the 2024 Annual Conference of the Australasian Society of Clinical Immunology and Allergy (ASCIA), taking place in Adelaide, Australia from September 3-6, 2024. Highlights from ASCIA Michael O'Sullivan, MBBS, FRACP, FRCPA, lead investigator, presented information on IgGenix's Phase 1 human clinical trial in peanut allergy "ACCELERATE Peanut." This study, which is active and screening, will evaluate the safety and tolerability of IGNX001, a therapeutic candidate which aims to offer the potential of rapid protection for peanut allergic patients. Derek Croote PhD, chief technology officer and co-founder of IgGenix, presented preclinical data on IGNX001 demonstrating robust protection against peanut-mediated mast cell activation, as well as against anaphylaxis in a murine model of peanut allergy. The complete preclinical findings were recently published in The Journal of Allergy and Clinical Immunology. "IGNX001 marks a potentially major step forward in treating peanut allergies," said Michael O'Sullivan, MBBS, FRACP, FRCPA, Consultant Clinical Immunologist at Fiona Stanley Hospital and Perth Children's Hospital, and Clinical Senior Lecturer at the University of Western Australia. "By using cutting edge research to re-engineer harmful IgE antibodies to IgG4 blocking antibodies that bind to allergens without causing reactions, this approach offers the potential for a faster, more effective alternative to current therapies. It has the potential to help change peanut allergy management, reducing severe reaction risks and improving quality of life for millions worldwide." Oral Presentation Title: Accelerating Towards Treatment Options for Adolescents and Adults With Peanut Allergy: Phase 1 Trial of Peanut-Specific Igg4 Antibody Therapeutic (IGNX001) Presenter: Michael O'Sullivan, MBBS, FRACP, FRCPA Poster Presentation Title: Preclinical Activity and GLP Safety Toxicology Data Ahead of Phase 1 Initiation of IGNX001 in Peanut Allergy Presenter: Derek Croote, PhD The abstracts can be accessed here. About IgGenix IgGenix is a privately held antibody discovery and development company taking a revolutionary approach to directly address allergies and atopic diseases. Through our proprietary SEQ SIFTER™ discovery platform, developed from foundational research of co-founders Stephen Quake, Kari Nadeau, and Derek Croote of Stanford University, we isolate and re-engineer fully human, high-affinity, allergen-specific antibodies designed to block and prevent the allergic cascade. By targeting common immunodominant allergens and their most important epitopes across the patient population, we intend to treat allergic pediatric and adult patients alike across food and environmental allergies. This novel approach may prevent life-threatening allergic reactions, saving lives and reducing the constant fear that affects millions of people living with severe allergies. SOURCE IgGenix

MediSecure voluntarily enters administration E-prescription service MediSecure entered into voluntary administration three weeks after it reported a "large-scale" ransomware attack . FTI Consulting's Vaughan Strawbridge and Paul Harlond have been appointed as administrators and liquidators of the embattled company, which used to provide a national service that delivers e-scripts to pharmacies. Strawbridge and Harlond will investigate how the company fell into the cyberattack and explore its options to recover assets. They will meet with MediSecure creditors sometime next week. Days before going into voluntary administration, MediSecure disclosed that it sought government funding to help with its response to the incident. However, its request was denied. In late May, reports came out saying that the stolen dataset from MediSecure allegedly appeared on the dark web . It most likely included data related to prescriptions and personal information of healthcare providers that MediSecure held up until 2023 when its national service contract ended . In response, the company said it is working to notify affected individuals. MediSecure has reached out to McGrathNicol Advisory who, in tandem with the National Cyber Security Coordinator, will assist in quickly determining the extent of the impact of the ransomware attack and all affected individuals. SA Ambulance Service to implement EMR South Australia has earmarked A$23.5 million ($15.6 million) over the next two years to introduce an electronic patient care record system for SA Ambulance Service. For the first time, ambulance crews will be able to enter patient notes directly from electronic devices, ditching the use of patient case cards and manual data entry. According to a media release, the ePCR will also be integrated with the Sunrise EMR system used across SA hospitals, facilitating quick access to patients’ ambulance records. Digital devices carrying the ePCR will be introduced gradually in over 500 ambulance fleets from the middle of 2025. Meanwhile, the SA government has also set aside A$10.7 million ($7 million) over the next four years for SAAS to onboard 16 additional p aramedic telehealth clinicians for the Clinical Telephone Assessment service. Currently manned by 15 clinicians, the service determines if a call requires an emergency response, suited to a more fitting care pathway, or if a patient can simply check with their GP. "Recruitment and training will commence immediately, with half of the additional clinicians expected to join the team later this year and the full 16 on board by mid-next year," the SA government said. Telehealth carts rolled out for North Queensland aged care Northern Queensland Primary Health Network will be rolling out mobile telehealth carts powered by Visionflex to 36 residential aged care homes. A telehealth cart includes a high-definition camera, full-size patient-facing monitor, computer equipment, and a range of USB peripherals for vital sign readings and patient monitoring. There are also accessibility options, such as live speech-to-text transcription and closed captioning, for patients with hearing and vision impairment. The federal government-funded telehealth carts serve as an option for aged care residents to access GP consultations, after-hours consultations, and specialist care services from their homes to prevent avoidable and unnecessary trips to the emergency department. Oncology IMS goes live at Fiona Stanley Hospital Fiona Stanley Hospital, a major hospital in Murdoch, is the first among healthcare sites under the South Metropolitan Health Service (SMHS) to implement a cancer information management system by Magentus. Late last year, Magentus was awarded the contract to deploy Charm Evolution across SMHS to serve as a single source of patient records. The system also provides care teams instant access to patient information in near-real time, standard protocols, and decision support. "Going live with Charm Evolution is helping us move away from reliance on paper records and manual prescribing. With a fully electronic prescribing system, we can improve patient safety by providing a single source of truth for treatment," Neil Doverty, group executive director of Fiona Stanley Fremantle Hospitals, shared in a statement. Rockingham General Hospital is also expected to go live with the Magentus IMS soon.

Murrumbidgee LHD trialling 'virtual hubs,' e-prescribing tool The Murrumbidgee Local Health District (MLHD) in southern New South Wales is pilot-testing a new state-sponsored telehealth programme that will allow people living in rural and remote areas to access quality healthcare closer to home, keeping them from travelling long distances. Based on a media release, the Virtual Hubs trial gives community members the ability to have remote health consultations in a dedicated space at a district facility equipped with tools required for telehealth, including a wall-mounted screen, camera, speaker, and keyboard and mouse. The Virtual Hubs are now being trialled in Junee Multipurpose Service (MPS), Tumut Hospital, Hillston MPS, Lake Cargelligo MPS, Hay MPS and Deniliquin Hospital. Meanwhile, clinicians across MLHD are also set to partake in the pilot of a new electronic prescribing programme early next year. The trial will allow nurse practitioners to write and send e-prescriptions, expanding their scope of practice. It is also envisioned to reduce administrative tasks such as handling paper scripts and minimising the risks of transcribing and drug interaction errors. The Boorowa MPS will be the first site of the pilot, followed by Western NSW LHD. Magentus' oncology IMS coming to WA's South Metropolitan Health Service The South Metropolitan Health Service (SMHS) in Western Australia is adopting Magentus' Charm Evolution oncology information management system. Charm Evolution was chosen to support SMHS's transition to a fully e-prescribing system that will serve as a "single source of truth for a patient’s treatment." The system is expected to provide clinicians with "more accurate" patient data and "instant" and remote access to near real-time information and standard protocols. Major SMHS hospitals, Fiona Stanley Hospital and Rockingham General Hospital, are set to go live with Charm Evolution in the "first half of next year," according to a media release. Western Sydney starts e-referral transition The Western Sydney LHD has started using electronic referrals via HealthLink with the first implementation done in the gastroenterology and gynaecology outpatient services at Blacktown Hospital. The NSW-wide project introduces e-referrals to improve the quality and safety of referral processes, which had become "too time-consuming." Starting next year, hospitals and community health services in Cumberland, Mount Druitt and Westmead will be accessible via e-referrals. Olinqua, Vayyar Care announces tech integration for preventing falls Olinqua has combined its hospital automation solution with Vayyar Care's 4D imaging radar technology to offer a new integrated system for managing mounting cases of falls. Vayyar Care's sensors can monitor fall risk factors such as increased bathroom usage, mobility loss, and changes in sleep patterns. Integrating these risk data into Olinqua's smart operating system is said to offer a proactive approach to detecting and p reventing falls. "[This technology] integration enables hospital and residential aged care staff to receive an immediate notification of a fall or suspected fall on a smartphone, with a graphical representation of the incident and its location on the Olinqua dashboard," Feargal O'Farrell, Vayyar Care director of ANZ Sales, further explained.